Georgia Tomaras
Chief, Division of Surgical Sciences
A. Geller Distinguished Professor for Research in Immunology
Professor in Surgery
Professor in Integrative Immunobiology
Professor in Molecular Genetics and Microbiology
Affiliate, Duke Global Health Institute
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Moodie Z, Li SS, Giorgi EE, Williams LD, Dintwe O, Carpp LN, et al. A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. Emerging microbes & infections. 2025 Dec;14(1):2485317.Schendel SL, Yu X, Halfmann PJ, Mahita J, Ha B, Hastie KM, et al. A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein. Cell reports. 2025 Apr;44(4):115499.Mielke D, Tuyishime M, Kelkar NS, Wang Y, Parks R, Santra S, et al. Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge. Vaccines. 2025 Mar 1;13(3).Montefiori DC, Ferrari G, Mielke D, Williams LD, Tomaras GD. Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1. Current HIV research. 2025 Mar;
See more publications at Scholars@Duke